IDH1 and glioma: In clinical studies, IDH1/2 mutations were observed in low-grade glioma and secondary glioblastoma (∼80%), and in acute myeloid leukemia (∼20%), angioimmunoblastic T-cell lymphomas (16%–17%) with worse prognosis [79–81, 77].